122 related articles for article (PubMed ID: 25634447)
1. Differential Interactions of Cytochrome P450 3A5 and 3A4 with Chemotherapeutic Agent-Vincristine: A Comparative Molecular Dynamics Study.
Saba N; Bhuyan R; Nandy SK; Seal A
Anticancer Agents Med Chem; 2015; 15(4):475-83. PubMed ID: 25634447
[TBL] [Abstract][Full Text] [Related]
2. Identification of a less toxic vinca alkaloid derivative for use as a chemotherapeutic agent, based on in silico structural insights and metabolic interactions with CYP3A4 and CYP3A5.
Saba N; Seal A
J Mol Model; 2018 Mar; 24(4):82. PubMed ID: 29502215
[TBL] [Abstract][Full Text] [Related]
3. Comparison of catalytic properties of cytochromes P450 3A4 and 3A5 by molecular docking simulation.
Niwa T; Yasumura M; Murayama N; Yamazaki H
Drug Metab Lett; 2014; 8(1):43-50. PubMed ID: 24484539
[TBL] [Abstract][Full Text] [Related]
4. Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia.
Egbelakin A; Ferguson MJ; MacGill EA; Lehmann AS; Topletz AR; Quinney SK; Li L; McCammack KC; Hall SD; Renbarger JL
Pediatr Blood Cancer; 2011 Mar; 56(3):361-7. PubMed ID: 21225912
[TBL] [Abstract][Full Text] [Related]
5. Differential Reversible and Irreversible Interactions between Benzbromarone and Human Cytochrome P450s 3A4 and 3A5.
Tang LWT; Verma RK; Yong RP; Li X; Wang L; Lin Q; Fan H; Chan ECY
Mol Pharmacol; 2021 Sep; 100(3):224-236. PubMed ID: 34210765
[TBL] [Abstract][Full Text] [Related]
6. Effect of CYP3A5 expression on vincristine metabolism with human liver microsomes.
Dennison JB; Jones DR; Renbarger JL; Hall SD
J Pharmacol Exp Ther; 2007 May; 321(2):553-63. PubMed ID: 17272675
[TBL] [Abstract][Full Text] [Related]
7. Comparative Study of Binding Pockets in Human CYP1A2, CYP3A4, CYP3A5, and CYP3A7 with Aflatoxin B1, a Hepato-Carcinogen, by Molecular Dynamics Simulation & Principal Component Analysis.
Saba N; Seal A
Curr Drug Metab; 2022; 23(7):521-537. PubMed ID: 35850656
[TBL] [Abstract][Full Text] [Related]
8. Active-site differences between substrate-free and ritonavir-bound cytochrome P450 (CYP) 3A5 reveal plasticity differences between CYP3A5 and CYP3A4.
Hsu MH; Johnson EF
J Biol Chem; 2019 May; 294(20):8015-8022. PubMed ID: 30926609
[TBL] [Abstract][Full Text] [Related]
9. Computational insights into the different catalytic activities of CYP3A4 and CYP3A5 toward schisantherin E.
Xue Y; Li J; Wu Z; Liu G; Tang Y; Li W
Chem Biol Drug Des; 2019 May; 93(5):854-864. PubMed ID: 30637977
[TBL] [Abstract][Full Text] [Related]
10. A Combined Molecular Docking/Dynamics Approach to Probe the Binding Mode of Cancer Drugs with Cytochrome P450 3A4.
Panneerselvam S; Yesudhas D; Durai P; Anwar MA; Gosu V; Choi S
Molecules; 2015 Aug; 20(8):14915-35. PubMed ID: 26287147
[TBL] [Abstract][Full Text] [Related]
11. Theoretical Insights into Imidazolidine Oxidation of Imidacloprid by Cytochrome P450 3A4.
Zheng ML; Li CR; Bai QH; Xiao H; Hu W; Xue Y; Gao JY
J Mol Graph Model; 2018 Mar; 80():173-181. PubMed ID: 29414036
[TBL] [Abstract][Full Text] [Related]
12. Differential oxidation of mifepristone by cytochromes P450 3A4 and 3A5: selective inactivation of P450 3A4.
Khan KK; He YQ; Correia MA; Halpert JR
Drug Metab Dispos; 2002 Sep; 30(9):985-90. PubMed ID: 12167563
[TBL] [Abstract][Full Text] [Related]
13. Comparison of kinetic parameters for drug oxidation rates and substrate inhibition potential mediated by cytochrome P450 3A4 and 3A5.
Niwa T; Murayama N; Emoto C; Yamazaki H
Curr Drug Metab; 2008 Jan; 9(1):20-33. PubMed ID: 18220568
[TBL] [Abstract][Full Text] [Related]
14. Clobetasol Propionate Is a Heme-Mediated Selective Inhibitor of Human Cytochrome P450 3A5.
Wright WC; Chenge J; Wang J; Girvan HM; Yang L; Chai SC; Huber AD; Wu J; Oladimeji PO; Munro AW; Chen T
J Med Chem; 2020 Feb; 63(3):1415-1433. PubMed ID: 31965799
[TBL] [Abstract][Full Text] [Related]
15. Gomisin A is a Novel Isoform-Specific Probe for the Selective Sensing of Human Cytochrome P450 3A4 in Liver Microsomes and Living Cells.
Wu JJ; Ge GB; He YQ; Wang P; Dai ZR; Ning J; Hu LH; Yang L
AAPS J; 2016 Jan; 18(1):134-45. PubMed ID: 26361765
[TBL] [Abstract][Full Text] [Related]
16. Severe Vincristine-induced Neuropathic Pain in a CYP3A5 Nonexpressor With Reduced CYP3A4/5 Activity: Case Study.
Bosilkovska M; Ing Lorenzini K; Uppugunduri CR; Desmeules J; Daali Y; Escher M
Clin Ther; 2016 Jan; 38(1):216-20. PubMed ID: 26565076
[TBL] [Abstract][Full Text] [Related]
17. Difference in Mechanism-Based Inhibition of Cytochrome P450 3A4 and 3A5 by a Series of Fluoroquinolone Antibacterial Agents.
Watanabe A; Takakusa H; Kimura T; Inoue SI; Kusuhara H; Ando O
Drug Metab Dispos; 2017 Mar; 45(3):336-341. PubMed ID: 27974381
[TBL] [Abstract][Full Text] [Related]
18. Spectroscopic studies and molecular docking on the interaction of organotin antitumor compound bis[2,4-difluoro-N-(hydroxy-⟨κ⟩O)benzamidato-⟨κ⟩O]diphenyltin(IV) with human cytochrome P450 3A4 protease.
Wei Y; Niu L; Liu X; Zhou H; Dong H; Kong D; Li Y; Li Q
Spectrochim Acta A Mol Biomol Spectrosc; 2016 Jun; 163():154-61. PubMed ID: 27049867
[TBL] [Abstract][Full Text] [Related]
19. Vincristine Disposition and Neurotoxicity Are Unchanged in Humanized CYP3A5 Mice.
Li Y; Kazuki Y; Drabison T; Kobayashi K; Fujita KI; Xu Y; Jin Y; Ahmed E; Li J; Eisenmann ED; Baker SD; Cavaletti G; Sparreboom A; Hu S
Drug Metab Dispos; 2024 Jan; 52(2):80-85. PubMed ID: 38071551
[TBL] [Abstract][Full Text] [Related]
20. Unraveling the Structural Basis of Selective Inhibition of Human Cytochrome P450 3A5.
Wang J; Buchman CD; Seetharaman J; Miller DJ; Huber AD; Wu J; Chai SC; Garcia-Maldonado E; Wright WC; Chenge J; Chen T
J Am Chem Soc; 2021 Nov; 143(44):18467-18480. PubMed ID: 34648292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
